On May 6, 2026, Cytokinetics, Inc. announced an underwriting agreement for a public offering of 9,859,155 shares of common stock at $71.00 per share, with expected net proceeds of approximately $760.2 million, including an option for underwriters to purchase an additional 1,478,873 shares.